Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
MedTech
Merck KGaA, Remepy team up on hybrid drugs for rare tumors
Merck KGaA is teaming up with Remepy to develop hybrid drugs that pair a pharmaceutical with a personalized, AI-driven digital component.
Natalie Missakian
Apr 28, 2026 7:00am
Storm secures $56M series C, launches ph. 2 sarcoma trial
Apr 16, 2026 10:12am
'Can it deliver?': Why Big Pharma has entered the quantum realm
Apr 10, 2026 7:20am
Merck KGaA drops pipeline asset from SpringWorks buyout
Mar 5, 2026 4:33pm
Sanofi's stunning CEO switch—Chutes & Ladders
Feb 13, 2026 8:30am
Fierce Pharma
Sanofi ousts Paul Hudson for Merck KGaA chief after 'bumpy ride'
Feb 12, 2026 4:26am
